US Stock MarketDetailed Quotes

AIM AIM ImmunoTech

Watchlist
  • 0.1279
  • -0.0079-5.82%
Close Feb 27 16:00 ET
  • 0.1225
  • -0.0054-4.22%
Post 17:48 ET
8.79MMarket Cap-0.27P/E (TTM)

About AIM ImmunoTech Company

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.

Company Profile

SymbolAIM
Company NameAIM ImmunoTech
Listing DateJul 19, 1996
Founded1966
CEOMr. Thomas K. Equels, Esq.
MarketAMEX
Employees28
Fiscal Year Ends12-31
Address2117 SW Highway 484
CityOcala
ProvinceFlorida
CountryUnited States of America
Zip Code34473
Phone1-352-448-7797

Company Executives

  • Name
  • Position
  • Salary
  • Thomas K. Equels, Esq.
  • Executive Vice Chairman of the Board, Chief Executive Officer and President
  • 1.08M
  • Peter W. Rodino, III
  • Chief Operating Officer, General Counsel & Secretary
  • 527.64K
  • Robert Dickey, IV
  • Chief Financial Officer
  • 64.48K
  • Dr. William M. Mitchell, M.D.,PhD
  • Chairman of the Board
  • 139.37K
  • Stewart L. Appelrouth
  • Independent Director
  • 139.37K
  • Nancy K. Bryan
  • Independent Director
  • 93.75K

Trending Stocks

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
Unlock Now
Discussing
Big Tech’s earnings season in full swing! Nvidia is the only one left
On Thursday, $Amazon (AMZN.US)$ stock fell after the firm reported Q4 adjusted earnings of $1.86/share, vs estimates of $1.50/share, on reve Show More